Results of Three Years’ Experience with the Deoxyuridine Suppression TestWickramasinghe S.N. · Saunders J.E.
Department of Haematology and MRC Experimental Haematology Unit, St. Mary’s Hospital Medical School, University of London, London
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
The results of deoxyuridine (dU) suppression tests performed on 400 marrow samples aspirated over a 3-year period are summarised. High dU-suppressed values were found in all patients with vitamin B12 or folate deficiency, in some patients receiving inhibitors of dihydrofolate reductase, in 4 of 19 epileptics receiving anticonvulsants and in 2 of 21 patients with iron deficiency anaemia. High dU-suppressed values were found even in those vitamin B12- or folate-deficient patients who had serum vitamin B12 and red cell folate levels within the normal range. Conversely, some patients with subnormal serum vitamin B12 levels (including 1 on high doses of penicillin, 1 on anticonvulsant therapy and 2 vegans) and some patients with subnormal red cell folate levels gave normal dU-suppressed values, and were considered not to suffer from the metabolic consequences of vitamin B12 or folate deficiency. All of the patients with megaloblastic erythropoiesis induced by the anti-purine drugs or cyclophosphamide, 4 patients with megaloblastic erythropoiesis associated with primary acquired sideroblastic anaemia, a chronic myeloproliferative disorder or subacute erythraemic myelosis and a proportion of the patients with megaloblastic erythropoiesis associated with anticonvulsant therapy, chronic alcoholism, acute myeloid leukaemia or myelomatosis also gave normal dU-suppressed values. The addition of 1 μg cyanocobalamin per millilitre of marrow culture together with the deoxyuridine caused a significant reduction in the dU-suppressed value in 86% of vitamin B12-deficient patients and the addition of 10 μg pteroylglutamic acid per millilitre of marrow culture caused a significant reduction in 91% of folate-deficient and 57% of vitamin B12-deficient patients.
© 1977 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.